IP Library Granted Patent US 10,379,105
Granted Patent B2
US 10,379,105 · App. 15/474,881 · Granted Aug 13, 2019

Antibodies to aripiprazole haptens and use thereof

Inventors: Eric Hryhorenko (Hilton, NY); Banumathi Sankaran (Lexington, MA); Thomas R. DeCory (Pittsford, NY); Theresa Tubbs (Rochester, NY); Linda Colt (Rochester, NY); Bart M. Remmerie (Ghent, BE); Rhys Salter (Doylestown, PA); Ronghui Lin (Ambler, PA)
Assignee: Janssen Pharmaceutica NV
G01N33/5008C07D215/227C07K16/44G01N33/5005G01N33/94C07K2317/14G01N2800/302G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,379,105
App. No.
15/474,881
Granted
Aug 13, 2019
Kind
B2
Abstract

Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Claims (32)

1. A method of producing an antibody which binds to aripiprazole, the method comprising:

(i) selecting a host for antibody production; and

(ii) inoculating the host with a conjugate of a compound of Formula I and an immunogenic carrier, wherein the host produces an antibody which binds to aripiprazole,

wherein:

R 1 is H,

CH 2 NH 2 , or

CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 2 is H,

NH 2 , or NHC(O)(CH 2 ) m CO 2 H;

R 3 is H; provided that either R 1 or R 2 must be H, and further provided that R 1 and R 2 may not all be H simultaneously;

m is 1, 2, 3, 4, or 5; and

n is 1, 2, 3, 4, or 5.

2. A method of producing a hybridoma cell line capable of producing a monoclonal antibody which binds to aripiprazole, the method comprising:

(i) selecting a host for antibody production;

(ii) inoculating the host with a conjugate of a compound of Formula I and an immunogenic carrier;

(iii) fusing a cell line from said inoculated host with a continuously dividing cell to create a fused cell capable of producing a monoclonal antibody which binds to aripiprazole; and

(iv) cloning the fused cell so as to obtain a hybridoma cell line,

wherein:

R 1 is H,

CH 2 NH 2 or

CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 2 is H,

NH 2 , or NHC(O)(CH 2 ) m CO 2 H;

R 3 is H; provided that either R 1 or R 2 must be H, and further provided that R 1 and R 2 may not all be H simultaneously;

m is 1, 2, 3, 4, or 5; and

n is 1, 2, 3, 4, or 5.

3. The method of claim 1 , wherein the immunogenic carrier is a protein.

4. The method of claim 3 , wherein the protein is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

5. The method of claim 2 , wherein the immunogenic carrier is a protein.

6. The method of claim 5 , wherein the protein is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

7. The method of claim 1 , wherein the antibody binding fragment is selected from the group of fragments consisting of Fv, F(ab′), F(ab′)2, scFv, minibody and diabody fragments.

8. The method of claim 1 , wherein the antibody is a monoclonal antibody.

Continuity (3)
Division 13971429 · Aug 20, 2013
Provisional Application 61691544 · Aug 21, 2012
Related Publication 20170204198A1 · Jul 20, 2017